Can Ayurveda Build a Stronger Pipeline from Research to Market?

Ayurveda stands at a critical juncture. Classical knowledge and modern research generate promising findings, yet many stop short of becoming commercially viable products.

The gap between laboratory insights and market-ready medicines limits wider adoption, especially in the management of non-communicable diseases.

The Central Council for Research in Ayurvedic Sciences has now placed this commercialization challenge at the center of its agenda.

Stronger scientific evidence, robust safety monitoring and deliberate technology transfer must convert research into credible, scalable products if Ayurveda is to compete alongside modern healthcare systems.

The Commercialization Gap in Ayurveda

CCRAS Director General Dr Rabinarayan Acharya made the priority clear at the National Symposium on Pharmacovigilance in Ayurveda held at the Central Ayurveda Research Institute in Bengaluru.

He called for scientific validation of innovations and sustained efforts to strengthen pharmacovigilance. Without these steps, research findings remain confined to academic circles and fail to reach patients or industry partners.

Key elements of the current gap include:

• Limited translation of classical formulations into standardized, market-ready technologies
• Insufficient clinical evidence that meets contemporary regulatory and physician expectations
• Incomplete safety monitoring systems that track adverse reactions in real-world use

Deputy Director General Dr Narayanam Srikanth reinforced the point by highlighting the need to prevent and report adverse drug reactions and to strengthen safety mechanisms for Ayurvedic medicines and therapies.

Also read: How Can India Pharma Bridge the Gap Between Innovation and Access

Building an Evidence Pipeline

Ayurveda already possesses foundational principles that can support a modern pipeline. Acharya noted that the concept of identifying and addressing adverse outcomes appears in classical texts such as the description of Basti Vyapad in the Charaka Samhita. These traditional insights provide a starting point for contemporary pharmacovigilance practices.

CCRAS is advancing several practical steps:

• Collaborations with the Indian Council of Medical Research in reproductive health, geriatric care and oncology
• Publications on the safety aspects of Panchakarma
• Evidence generation for specific interventions such as Punarnava Mandoora

The symposium itself, themed “Safe Care for Non-Communicable Diseases – Safe Care for Life,” brought researchers, physicians and experts together to examine how evidence-based Ayurvedic care can address NCDs.

The discussions underscored that Ayurveda’s growing positioning alongside modern medicine makes rigorous evidence generation and safety monitoring essential for broader acceptance.

From Research to Market-Ready Products

Closing the commercialization gap requires a continuous chain in which classical formulations must undergo standardization, preclinical research, clinical validation, and ongoing safety surveillance.

CCRAS views this sequence as the pathway to credibility. When research findings successfully move through each stage, industry can adopt them with greater confidence, physicians can prescribe them on stronger grounds, and patients can access therapies backed by transparent safety data.

Ayurveda can build a stronger pipeline from research to market only when scientific validation and pharmacovigilance become integral, not optional, parts of the development process.